secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001689548-24-000058
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Q1 net loss $39.6M; cash $451.2M, positive PRAX-628 data; Essential3 topline H2 2024
--------------------------------------------------------------------------------

- Net loss $39.6M in Q1 2024 vs $37.5M a year ago; R&D expense $27.0M, G&A $15.3M.
- Cash $451.2M at April 30, 2024, from two public offerings ($161.6M Jan, $215.8M Apr); runway into 2027.
- PRAX-628 Phase 2a PPR study: 100% response; 80% complete at 15mg, 100% at 45mg; focal onset seizure studies start H2 2024 and H1 2025.
- Ulixacaltamide Essential3 trial: >50K pre-screening forms, >7K referrals; topline H2 2024 to support NDA in 2025.
- PRAX-562 EMBOLD study in pediatric DEEs: randomization completed; topline results expected Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000058/0001689548-24-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000058/prax-20240513.htm
  HTML page:      https://secwatch.observer/filing/0001689548-24-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer